Carl Schmid discusses on a National Consumers League webinar current federal advocacy efforts to ensure that copay assistance for prescription drugs counts. This includes comments on two regulations, a congressional bill, and recent litigation initiated by HIV+Hep and two diabetes groups.
Carl Schmid presents to NAIC Special Committee on Race & Insurance on how insurance benefit design impacts prescription drug access for racial and ethnic communities and suggestions for overcoming access barriers by reducing utilization management measures, lowering cost-sharing, offering standardized plans, and enforcing ACA non-discrimination policies.
Carl Schmid discusses the implications of the USPSTF Grade A rating of HIV PrEP to patients, providers, and payers.
Examines how insurance benefit design, including high deductibles and co-insurance, impact prescription drug access, along with the importance of copay assistance and how states are ensuring that it count towards beneficiary cost-sharing obligations.
Examines the federal requirement for private insurers to cover PrEP without cost-sharing, state actions to comply, transparency issues, and next steps for enforcing the requirement.